Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial
- 1 November 2008
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (31), 5027-5035
- https://doi.org/10.1200/jco.2007.14.6597
Abstract
Patients with early breast cancer who receive anthracycline-containing chemotherapy experience improved relapse-free (RFS) and overall survival (OS) compared with those who receive non–anthracycline-containing chemotherapy. Such benefit, however, may be restricted to women whose tumors have specific molecular characteristics. We tested the hypothesis that HER2, epidermal growth factor receptor (EGFr)/HER1, HER3, Ki67, and topoisomerase IIα expression are predictive of outcome after anthracycline-based chemotherapy. Tissue microarrays from 322 of 374 women in the BR9601 trial, which compared cyclophosphamide, methotrexate, and fluorouracil (CMF) with epirubicin followed by CMF (epi-CMF), were analyzed for HER1, 2, 3, 4; Ki67; and topoisomerase IIα protein expression and for HER2/topoisomerase IIα gene amplification. Their relationships to RFS and OS were investigated, and multiple regression analysis was used to identify interactions. A significant interaction was seen between tumors with normal HER1, HER2 fluorescent in situ hybridization (FISH), or HER3 levels and the enhanced benefit from epi-CMF versus CMF for RFS (hazard ratio [HR], 0.36; HR for overexpressed HER1 or HER2 FISH or HER3, 0.92; P = .035) and for OS (HR, 0.30; HR for overexpressed HER1 or HER2 FISH or HER3), 0.98; P = .023). Neither Ki67 nor TIIα expressions or gene alterations showed clear predictive value for benefit from the addition of the anthracycline. Patients with HER2 amplified and those with HER1, HER2 FISH, or HER3-positive tumors did not benefit from the addition of epirubicin to CMF. Conversely, patients with HER2 nonamplified and HER1 through HER3–negative tumors showed significantly increased RFS and OS rates when treated with epi-CMF compared with CMF.Keywords
This publication has 32 references indexed in Scilit:
- Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast CancerNew England Journal of Medicine, 2006
- Observer variation in immunohistochemical analysis of protein expression, time for a change?Histopathology, 2006
- Anthracyclines and the Tailoring of Treatment for Early Breast CancerNew England Journal of Medicine, 2006
- REporting recommendations for tumour MARKer prognostic studies (REMARK)British Journal of Cancer, 2005
- Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5Journal of Clinical Oncology, 2005
- Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIα for anthracycline chemotherapy in locally advanced breast cancerBreast Cancer Research and Treatment, 2005
- Expression of the HER1–4 family of receptor tyrosine kinases in breast cancerThe Journal of Pathology, 2003
- HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast CancerJournal of Clinical Oncology, 2003
- Coexpression of EGFr, HER2, HER3 and HER4 in primary human breast carcinomaEuropean Journal Of Cancer, 2001
- HER-2 amplification evaluated by fluorescence in-situ hybridization (FISH) as a predictive marker in node-positive (N+) breast cancer (BC) patients (pts) randomly treated with CMF or an anthracycline-based therapyEuropean Journal Of Cancer, 2001